Circulating TGF‐β1 Increases During Vaginal Progesterone Therapy in Women With a Short Cervix
Scandinavian Journal of Immunology · 2026-11 · 104 (5)
DOI: 10.1111/sji.70165 ↗Abstract
ABSTRACT Progesterone is an effective tool for the secondary prevention of spontaneous preterm birth. The aim of this prospective exploratory pilot study was to evaluate the effect of progesterone administration on the number of regulatory T cell (Treg) populations and on the concentrations of the immunoregulatory cytokines IL‐10 and TGF‐β1 during in vivo progesterone treatment in women at risk of preterm delivery. Pregnant women with a singleton pregnancy (22–30 weeks of gestation) who were at risk of spontaneous preterm delivery and required progesterone therapy were included ( n = 21). Peripheral blood was sampled before progesterone administration and twice thereafter during treatment. Seventeen women attended the second visit, while only seven attended the third visit. The control group consisted of prospectively recruited low‐risk women ( n = 8). Treg numbers were determined by flow cytometry, and plasma concentrations of TGF‐β1 and IL‐10 were measured by ELISA. In women at risk, plasma TGF‐β1 concentrations increased significantly between the first and second sampling ( p ≤ 0.01) and remained at a similar level at the third sampling. In contrast, TGF‐β1 levels in the control group remained low without statistically significant change. IL‐10 concentrations were generally low in both groups. This pilot study was associated with an increase in the immunoregulatory cytokine TGF‐β1 following progesterone administration. Although TGF‐β1 is produced by several cell types in addition to Tregs, our findings raise the possibility that progesterone reinforces an immunoregulatory pathway relevant to the maintenance of pregnancy in women at risk of preterm birth; however, the present study does not establish this mechanism.
EUVIMED